Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy.

Martha GroganMargot K DavisMaria G Crespo-LeiroMarla B SultanBalarama GundapaneniFranca Stedile AngeliMazen Hanna

Published in: European journal of heart failure (2024)

Tafamidis reduced HRQoL decline in patients with ATTR-CM. Patients continuously treated with tafamidis for 60 months demonstrated stabilized HRQoL. In patients who initially received placebo in ATTR-ACT, tafamidis reduced the decline in HRQoL during the LTE study.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
heart failure
prognostic factors
peritoneal dialysis
clinical trial
phase iii
patient reported